Articles On Telix Pharmaceuticals (ASX:TLX)

Australian shares rebounded strongly this session but could not avert a fourth straight weekly decline as financial markets continued to factor in the risk of a global slowdown as rates rise and China pursues zero-Covid. An end-of-week r...

A relief rally lifted the ASX 200 back above the 7000 level as a pause in this week’s bloodletting on Wall Street brought buyers back to market. The S&P/ASX 200 bounced 95 points or 1.36 per cent to 7036 by mid-session. The rally bro...

You might be sick of hearing this, but turbulent times like now mean it’s more important than ever to retain a long-term view of ASX shares. You might look at a particular stock and be horrified that it has dropped half its value this year...

The share market logged its weakest close since January as the tech sector slumped to a two-year low and the dollar fell below 69 US cents. Borrowing-dependent growth stocks bore the brunt as the S&P/ASX 200 tumbled 124 points or 1.7...

Highlights: Race Oncology is riding high with governance approval for human trial of its new therapy Zantrene®. The cancer drug will be studied in patients with extramedullary Acute Myeloid Leukaemia (AML) or high-risk Myelodysplastic...

Biotechnology ASX shares have been one of the biggest victims of persistent inflation and rising interest rate fears over the past 6 months.  The S&P/ASX 300 Pharmaceuticals & Biotechnology (ASX: AXPBKD) has lost about 15% over tha...

Some of the worst-performing corners of the market enjoyed a day in the sun after a relief rally on Wall Street inspired the ASX’s first advance this week. Gold miners, tech companies and small and micro caps outperformed as the S&P/...

Tech and commodity stocks steered the share market towards its first gain of the week following Wall Street’s best session since 2020. The S&P/ASX 200 overcame an early wobble to advance 44 points or 0.6 per cent by mid-session. T...

MELBOURNE, Australia and INDIANAPOLIS, May 5, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in the ‘STARLITE 2’ Phase II study of the Company’s invest...

Highlights Gains in the market were broad-based today with all the 11 individual sectors ending in the positive territory. The IT sector rose 2.25% on Friday followed by Telecom and Consumer Discretionary, which added 1.89% and 1.46% r...

The share market ended a volatile month on a strong note, advancing for a second day ahead of a likely rate rise next week. The S&P/ASX 200 climbed 78 points or 1.06 per cent. The rally trimmed the benchmark’s loss for the month to 6...

A broad rally carried the share market towards a second day of gains at the end of a challenging month for investors. All 11 sectors rose as the S&P/ASX 200 put on 58 points or 0.79 per cent. The advance trimmed the index’s loss for...

The first few months of 2022 has seen share market volatility like we could not even imagine last year. This means that quite a few businesses have seen their stock fall like a stone. Yet their operations and fortunes may not have changed...

A week-long rally soured with the share market’s heaviest loss in two months as investors took profits ahead of the long weekend. The S&P/ASX 200 slumped 119.5 points or 1.57 per cent to its first loss in six sessions. The reversal p...

22 Apr 2022 - Telix Pharmaceuticals (ASX:TLX) reported on its March quarter, with focus placed on its prostate cancer product.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is sliding today and is now 1.96% in the red at $4.51. Investors appear to have been unimpressed by Telix’s quarterly activities and cash flow report today, with trading volume less tha...

The share market backed off an eight-month high after a sharp reversal on Wall Street stoked risk aversion ahead of the long weekend.   The S&P/ASX 200 skidded 124 points or 1.63 per cent by mid-session. The decline ended a five-sess...

A disappointing quarterly from mining heavyweight BHP crimped a fifth day of share market gains as the ASX 200 edged closer to record territory. The Australian benchmark climbed to within 0.5 per cent of last year’s peak, rising 31 point...

ASX 200 healthcare shares have struggled for the past six months, let’s face it. After peaking at 52-week highs of 47,760 back in September 2021, the S&P/ASX 200 Health Care Index (ASX: XHJ) now rests at 39,861. That’s a 16.5% decline...

Aussie shares pared solid early gains as rising rates and stronger-than-expected Chinese consumer prices sharpened global inflation worries ahead of tomorrow’s US data. The S&P/ASX 200 slashed an early 47-point surge to seven points...

11 Apr 2022 - Telix Pharmaceuticals (ASX:TLX) has entered into a licence agreement with Eli Lilly, which grants Telix rights to develop and commercialise radiolabelled forms of Lil…

Telix Pharmaceuticals (ASX:TLX) signs an exclusive licence agreement with Eli Lilly to develop its cancer antibody medication olaratumab Telix will pay Lilly an initial US$5 million (A$6.7 million) for the rights to its radiolabelled forms...

The share market hit a four-session high before turning negative as US futures signalled potential weakness tonight. The S&P/ASX 200 reached mid-session a point or 0.01 per cent lower after earlier gaining 47 points.  The early rally...

MELBOURNE, Australia and INDIANAPOLIS, April 11, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, "Telix", the "Company") today announces that it has entered into a licence agreement with Eli Lilly and Company ("Lilly") under...

S&P/ASX 200 healthcare index modestly up 0.16% for week Gut health company Microba falls on IPO Rhythm Biosciences bowel cancer blood screening test milestone Have a habit of forgetting where you put your keys or mobile phone? You ma...

MELBOURNE, Australia, April 6, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) welcomes the listing of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) (PSMA-PET) imaging for p...

Gains in the resources, banking and technology sectors contributed to a 6.9% total return for the ASX200 in March, as Australia continued to outperform global equity markets. -The ASX200 gained 6.9% (total return) during March-Value continu...

Telix Pharmaceuticals (ASX:TLX) has announced that its prostate cancer imaging agent Illuccix, also known as 68Ga-PSMA-11 injection, is now commercially available in the US.

ASX 200 extends winning streak US bonds have sharply inverted, sparking concerns of a potential recession China says it has found a new Omicron sub-variant   It was a sea of green today on the ASX, as local investors shrugged off a rapid...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price took off today after the company released news of its lead product and a $23 million funding package.   Telix’s prostate cancer imaging agent Illuccix is now available for order in the U...

The share market ended within 80 points of this year’s highest close as a mining rally rolled on amid speculation about a commodities “supercycle”. The S&P/ASX 200 rallied 20 points or 0.27 per cent to 7513.7. The index hit its 2022...

A lithium-led mining rally kept the ASX on track for this year’s highs.   The S&P/ASX 200 climbed 22 points or 0.3 per cent by mid-session. The advance lifted the index briefly to within 100 points of this year’s peak. Lithium min...

04 Apr 2022 - A snapshot of the stocks on the move featuring Pepper Money (ASX:PPM), Telix Pharmaceuticals (ASX:TLX) & Iluka Resources (ASX:ILU).

MELBOURNE, Australia, April 4, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it is part of a $71.2 million Australian Precision Medicine Enterprise (APME) Project, which has been aw...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in ASX health stocks. Good news for coffee lovers, particularly those w...

Non-Executive Director Oliver Buck to retire at the Annual General Meeting Tiffany Olson, experienced U.S.-based pharma executive appointed as independent Non-Executive Director MELBOURNE, Australia and INDIANAPOLIS, March 31, 2022 /...

MELBOURNE, Australia and INDIANAPOLIS, March 29, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the launch of PSMA PET/CT[1] Today, a five-part video series, featuring leading theranostic...

Highlights The ASX 200 closed higher today, gaining 51.90 points or 0.70% to 7,464.30. Wall Street's gains overnight and revived hopes for fresh cease-fire talks between Russia and Ukraine seem to be lifting investor sentiment. In Aus...

The S&P/ASX Emerging Companies (XEC) Index is racking about 0.3% higher on Tuesday, while the benchmark ASX 200 (XJO) rose 0.7%, buoyed by a resurgent tech sector and a strong performance from consumer discretionary companies ahead of t...

MELBOURNE, Australia and INDIANAPOLIS, March 29, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designati...

ASX 200 notched up sixth day of gains Retailers, tech were best performing sectors Fed Budget to be delivered at 7.30pm AEDT tonight Retailers, Tech lead the way Local shares head into tonight’s Federal Budget in flying colours after clo...

The share market closed at a ten-week high as blue-chip healthcare, banking and consumer stocks took the lead during a pause in a two-week commodities rally.   The S&P/ASX 200 climbed 52 points or 0.7 per cent to its strongest close...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.7% to 7,467.2 points. Four ASX shares that are climbing more than most today are listed below...

Tech stocks took up the running as the Australian share market rose for a sixth session ahead of tonight’s Federal Budget. The S&P/ASX 200 climbed 59 points or 0.8 per cent to its highest since mid-January. The I.T. sector jumped...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is heading north during late morning trade following a company announcement. At the time of writing, the biotechnology company’s shares are selling for $4.56 apiece, up 9.88%. What did...

MELBOURNE, Australia and LIÈGE, Belgium, March 29, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement with Xiel Limited (Xiel) for the distribution of Telix’...

The Australian market remains resilient to the threat of higher energy prices with the S&P/ASX 200 (ASX: XJO) gaining another 0.3% to finish the week. The result was driven by a rally in the energy, materials and utilities sectors, whic...

The share market sealed back-to-back weekly gains with a fourth straight advance after strong economic data and a pause in energy prices lifted Wall Street. The S&P/ASX 200 climbed 19 points or 0.26 per cent. The rally lifted the ben...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to finish the week on a high. At the time of writing, the benchmark index is currently up 0.4% to 7,414.6 points. Four ASX shares that have failed to follow the market h...

A rebound on Wall Street helped propel the ASX towards a fourth straight gain as a two-week mining rally rolled on. The S&P/ASX 200 climbed 38 points or 0.52 per cent by mid-session. The rally lifted the benchmark above 7400 for the...